Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-702 IN CHINA

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that OT-702 (aflibercept biosimilar) has completed the enrollment of 416 patients for its phase III clinical trial on March 3, 2023, symbolizing the completion of patient enrollment for the phase III clinical trial of OT-702 in China.

The phase III clinical trial of OT-702 is designed to be a randomized, double-blind, parallel-controlled and multicenter clinical trial to compare the efficacy and safety of OT-702 to EYLEA® (aflibercept intravitreous injection) in the treatment of wet age-related macular degeneration. Pursuant to a collaboration and exclusive promotion agreement entered in October 2020 (the "**Agreement**"), the Group jointly developed OT-702 with Shandong Boan Biotechnology Co., Ltd. ("**Boan Biotech**") (6955.HK), a subsidiary of Luye Pharma Group Ltd. (2186.HK), in the phase III clinical trial of OT-702. The Group has obtained an exclusive right from Boan Biotech to promote and commercialize OT-702 in mainland China under the Agreement.

OT-702 is a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection. As a biosimilar to EYLEA® (aflibercept intravitreous injection), OT-702 is indicated for the treatment of patients with neovascular wet age-related macular degeneration, macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). As a soluble trapping receptor, OT-702 can bind to cytokines such as VEGF-A, VEGF-B and P1GF, inhibit the downstream signaling pathway of VEGFR, inhibit neovascularization, and reduce vascular permeability, thereby treating pathological neovascularization of the retina and choroid eye diseases. The head-to-head comparison of OT-702 to EYLEA® (aflibercept intravitreous injection) showed a high degree of similarity in both physical and chemical properties and biological activities. The results of its phase I clinical trial showed that OT-702 has a good safety and tolerability profile.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-702 (aflibercept biosimilar) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, March 13, 2023

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.